Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
Intravenous (IV) ketamine is effective in adults resistant to depression. The response was similar to that seen in younger patients, two new studies show.
Read Full NewsThe pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.
Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.
Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO
1.
For fit patients with CLL, frontline venetoclax-ibrutinib improves survival.
2.
Waist circumference outshines BMI as obesity-related cancer risk marker in men, but not women
3.
Next Day Mood Is Affected by Ability to Recover From Work.
4.
Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC
5.
Review looks at potential treatment targets in the tumor microenvironment.
1.
Understanding Sickle Cell Anemia: Causes, Symptoms, and Treatment Options
2.
Gene Signatures and Their Implications in Oncology: Decoding the Blueprint for Personalized Cancer Treatment
3.
Exploring Innovative Approaches to Esophageal Cancer Treatment
4.
Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care
5.
Unlocking the Potential of Red Bone Marrow in the Formation of Blood Cells
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
2.
Navigating the Complexities of Ph Negative ALL - Part XI
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge